Display options
Cite
Urueña A, Micone P, Magneres C, et al. Cost-Effectiveness Analysis of Switching from Trivalent to Quadrivalent Seasonal Influenza Vaccine in Argentina. Vaccines (Basel). 2021;9(4)doi: 10.3390/vaccines9040335.
Urueña, A., Micone, P., Magneres, C., Mould-Quevedo, J., & Giglio, N. (2021). Cost-Effectiveness Analysis of Switching from Trivalent to Quadrivalent Seasonal Influenza Vaccine in Argentina. Vaccines, 9(4), . https://doi.org/10.3390/vaccines9040335
Urueña, Analia, et al. "Cost-Effectiveness Analysis of Switching from Trivalent to Quadrivalent Seasonal Influenza Vaccine in Argentina." Vaccines vol. 9,4 (2021). doi: https://doi.org/10.3390/vaccines9040335
Urueña A, Micone P, Magneres C, Mould-Quevedo J, Giglio N. Cost-Effectiveness Analysis of Switching from Trivalent to Quadrivalent Seasonal Influenza Vaccine in Argentina. Vaccines (Basel). 2021 Apr 01;9(4). doi: 10.3390/vaccines9040335. PMID: 33916048; PMCID: PMC8067173.
Copy Download .nbib Format: NLM
Share it on

Vaccines (Basel). 2021 Apr 01;9(4). doi: 10.3390/vaccines9040335.

Cost-Effectiveness Analysis of Switching from Trivalent to Quadrivalent Seasonal Influenza Vaccine in Argentina.

Vaccines

Analia Urueña, Paula Micone, Cecilia Magneres, Joaquin Mould-Quevedo, Norberto Giglio

Affiliations

  1. Centro de Estudios para la Prevención y Control de Enfermedades Transmisibles, Universidad Isalud, Buenos Aires C1095AAS, Argentina.
  2. Hospital Carlos G Durand, Buenos Aires 1405, Argentina.
  3. Seqirus S.A., Buenos Aires B1636AKJ, Argentina.
  4. Seqirus USA Inc., Summit, NJ 07901, USA.
  5. Hospital de Niños Ricardo Gutierrez, Buenos Aires 1425, Argentina.

PMID: 33916048 PMCID: PMC8067173 DOI: 10.3390/vaccines9040335

Abstract

The burden of seasonal influenza disease in Argentina is considerable. The cost-effectiveness of trivalent (TIV) versus quadrivalent influenza vaccine (QIV) in Argentina was assessed. An age-stratified, static, decision-tree model compared the costs and benefits of vaccination for an average influenza season. Main outcomes included: numbers of influenza cases; general practitioner (GP) visits; complicated ambulatory cases; hospitalizations; deaths averted; and costs per quality-adjusted life years (QALYs) gained. Epidemiological data from Argentina for 2014-2019 were used to determine the proportion of A and B strain cases, and the frequency of mismatch between vaccine and circulating B strains. To manage uncertainty, one-way and probabilistic sensitivity analyses were performed. Switching from TIV to QIV would prevent 19,128 influenza cases, 16,164 GP visits, 2440 complicated ambulatory cases, 524 hospitalizations, and 82 deaths. Incremental cost-effectiveness ratios (ICERs) per QALY were 13,590 and 11,678 USD from the payer's and societal perspectives, respectively. The greatest health benefits and direct medical cost savings would occur in ≥ 65-year-olds. One-way sensitivity analyses demonstrated the principal drivers of ICER to be vaccine acquisition costs, environmental B strain predominance, and B strain mismatch. Introducing QIV in Argentina would be beneficial and cost-effective relative to TIV, particularly in older adults.

Keywords: Argentina; QIV; TIV; cost-effectiveness; influenza; quadrivalent; trivalent; vaccine

References

  1. PLoS One. 2015 Jul 29;10(7):e0133606 - PubMed
  2. J Infect Dis. 2004 Oct 15;190(8):1369-73 - PubMed
  3. BMC Med. 2017 Sep 8;15(1):166 - PubMed
  4. Clin Infect Dis. 2010 Nov 1;51(9):997-1004 - PubMed
  5. Cochrane Database Syst Rev. 2010 Jul 07;(7):CD001269 - PubMed
  6. Hum Vaccin Immunother. 2017 Apr 3;13(4):867-876 - PubMed
  7. Influenza Other Respir Viruses. 2021 May;15(3):407-412 - PubMed
  8. Lancet. 2020 May 16;395(10236):e84 - PubMed
  9. Hum Vaccin Immunother. 2020 Apr 2;16(4):827-835 - PubMed
  10. Sci Total Environ. 2021 Mar 8;778:146198 - PubMed
  11. J Infect. 2014 Apr;68(4):363-71 - PubMed
  12. Cochrane Database Syst Rev. 2018 Feb 01;2:CD004876 - PubMed
  13. Hum Vaccin Immunother. 2017 Apr 3;13(4):877-888 - PubMed
  14. Hum Vaccin Immunother. 2016 Oct 2;12(10):2712-2717 - PubMed
  15. PLoS One. 2014 Jun 06;9(6):e98437 - PubMed
  16. Braz J Infect Dis. 2018 Jan - Feb;22(1):1-10 - PubMed
  17. BMC Infect Dis. 2009 Jan 17;9:2 - PubMed
  18. Cochrane Database Syst Rev. 2012 Aug 15;(8):CD004879 - PubMed
  19. Hum Vaccin Immunother. 2012 Mar;8(3):312-22 - PubMed
  20. Pharmacoeconomics. 2016 Sep;34(9):939-51 - PubMed
  21. BMC Infect Dis. 2015 Oct 27;15:465 - PubMed
  22. Vaccine. 2020 Apr 29;38(20):3682-3689 - PubMed
  23. Expert Rev Pharmacoecon Outcomes Res. 2017 Jun;17(3):249-265 - PubMed
  24. Rev Panam Salud Publica. 2017 Jun 08;41:e76 - PubMed
  25. JAMA. 2020 May 26;323(20):2085-2086 - PubMed
  26. Virology. 1990 Mar;175(1):59-68 - PubMed
  27. BMC Public Health. 2020 Sep 9;20(1):1374 - PubMed
  28. Value Health. 2016 Dec;19(8):964-975 - PubMed
  29. Emerg Infect Dis. 2009 Dec;15(12):2004-7 - PubMed
  30. Hum Vaccin Immunother. 2018;14(8):1867-1873 - PubMed
  31. Hum Vaccin Immunother. 2016 Sep;12(9):2269-77 - PubMed
  32. Vaccine. 2020 Jan 29;38(5):1057-1064 - PubMed
  33. BMC Med. 2013 Jun 25;11:153 - PubMed
  34. Arch Iran Med. 2020 Apr 01;23(4):239-243 - PubMed
  35. PLoS One. 2019 Aug 8;14(8):e0219595 - PubMed

Publication Types